fda tirzepatide announcement Tirzepatide, FDA, and Compounding: Understanding the Current Landscape ZEPBOUND gets a NEW FDA

Tirzepatide Shown to Tackle Hypogonadism from ENDO 2025: CME INDIA Clinical Pearls: Tirzepatide in Obesity-Associated Hypogonadism @Rssdi_official @IndiaESI @AskDrShashank @banshisaboo @DrAmbrishMithal @dramitaol @KapoorNitinDr @DrShubhaSandill @DrKhushboo_Endo @ Key Takeaways: Metabolic hypogonadism in obese men is an underdiagnosed but clinically significant condition, closely linked with insulin resistance and increased diabetes risk

However, the authors included only six RCTs involving tirzepatide and, as opposed to our meta-analysis, did not provide information on comparative effects across different doses of the two medications [55]

Are GLP-1s and GIPs only used for people with diabetes, or can they support metabolic health in other individuals as well

The starting dosage for weight management is usually lower than that used for diabetes treatment, and it is gradually increased to minimize gastrointestinal side effects

Safety depends less on the molecule and more on who made the vial, how it was tested, and how it was handled

The formula is: dose (mg) divided by concentration (mg/mL) multiplied by 100